Loading...
•
Jun 30, 2022
ADMA Biologics Q2 2022 Earnings Report
ADMA Biologics experienced significant revenue growth, improved gross margins, and narrowed net losses in Q2 2022.
Key Takeaways
ADMA Biologics reported a 90% year-over-year increase in total revenue, reaching $33.9 million for Q2 2022. The company's gross profit increased to $7.8 million, and net losses were narrowed to $13.8 million. ADMA anticipates total 2022 revenues will exceed $130 million.
Total revenues increased by 90% year-over-year to $33.9 million in Q2 2022.
Gross profit grew to $7.8 million, driven by higher margin products.
Net losses narrowed to $13.8 million, reflecting improved gross margins.
The company expects total 2022 revenues to exceed $130 million.
Forward Guidance
ADMA anticipates total 2022 revenues will exceed $130 million. The company continues to anticipate generating approximately $250 million or more in topline revenue in 2024, and approximately $300 million or more thereafter. ADMA continues to forecast achieving corporate gross margins in the range of 40-50% and net income margins in the range of 20-30%.
Positive Outlook
- Total 2022 revenues are expected to exceed $130 million.
- Continued gross profit expansion is expected as 2022 progresses.
- Net losses are expected to narrow as 2022 progresses.
- Revenue of $250 million or more is anticipated in 2024.
- Revenue of $300 million or more is anticipated thereafter.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...